Bruno A. Costa, MD
@mdbrunocosta
Hem/Onc Fellow @MDAndersonNews | Myeloma & Cell Therapy Researcher | Former HPM Fellow & IM Resident @MountSinaiNYC | First-Gen Doc from @ufcinforma 🇧🇷
One of the happiest moments of my life: matched into my #1 choice for Hem/Onc fellowship—@MDAndersonNews, here we go! I am grateful beyond words to every single person who supported, taught, inspired, and believed in me along this journey, and I promise to make the most of this…
Ongoing #video summaries of the #Top10Tips paper for #hpm on #survonc published in @PalliativeMed_j Presenting Tip 5⃣ #FinTox 💰💸 @fumikochino @yzafar @Mombada1 @MonikaJ95971150 @drtulsijose @bosnjaksupport @ChandrikhaC @GretchenMcnally @aarsh_a_desai @IshwariaMD…
1/ 🚨 Out Now @TheLancetOncol DREAMM-7 Update (Phase 3): Belantamab mafodotin + bortezomib + dexamethasone (BVd) vs daratumumab + Vd (DVd) in relapsed/refractory multiple myeloma after ≥1 prior line of therapy. Results are in—. 🧬🔥 #mmsm #MedEd #myeloma #MedTwitter #USMIRC…
One of the issues with "first generation" bispecific TCE in MM is that doses and schedules were developed on the assumption that levels have to be > EC90 all the time. Empirically we are learning that is not the case, less is actually safer and may be better.
That’s what I personally do as SOC, although MASTER-2 and TEC-4 have used 3.0 mg/kg per month at this juncture based on PK data. My humble take - as long as the uninvolved light chains are undetectable, whatever dose frequency you use is working!
1/ FASCINATING @BloodPortfolio work by 🇩🇪 team: single cycle of K after commercial BCMA CAR-T leads to ⬆️ BCMA and sometimes responses if T cells still there! While pom post-CAR-T ? works on T cells, this works on #MMsm cells in unique way. Needs Ph1-2 study, but fascinating!
#Myeloma Paper of the Day: BCMA is a highly short-lived protein that undergoes K48-linked polyubiquitylation at plasma membrane & carfilzomib enhances the efficacy of BCMA-directed CAR T cells against both PI-sensitive and refractory myeloma cells: pubmed.ncbi.nlm.nih.gov/40638685/. #mmsm
Happy July to all new fellows! 🎉 @FionnualaCrowle and I are excited to share our new article: Balancing the Scales: Real-Life Fellows’ Perspectives on Navigating Work-Life Balance in Oncology Training and Beyond | ASCO Connection connection.asco.org/do/balancing-s… We truly enjoyed writing…
Linvoseltamab (BCMA-CD3 Tcell bispecific) is now @US_FDA approved based off LINKER-MM1 study in R/R Multiple Myeloma (at least 4 prior lines of Rx): - ORR was 70% - DoR: 89% at 9mos and 72% at 12 mos - AEs: CRS, ICANS (mainly low grade), Infections #HemeTwitter #mmsm
Just out: FDA grants accelerated approval to linvoseltamab for treatment of relapsed/refractory myeloma. It is the 3rd BCMA bispecific antibody approved for myeloma. I welcome the choice that patients and physicians have. ajmc.com/view/fda-appro…
🚨 for fellows / junior faculty - @JCO_ASCO is soliciting Art of Oncology submissions through Narrative Medicine contest. Write about a compelling pt experience you’ve learned from - we all will benefit from reading it in JCO! Submissions due Aug 31. ascopubs.org/jco/art-oncolo…
Once more congratulations @NoopurRajeMD for a very successful program lots of case discussions and inspiring educational lectures
@Myeloma_Society educational workshop in Marrakech with @NikhilMunshiMD @SagarLonialMD @myelomaMD @mbeksac56 @szusmani ..excellent talks and great cases.. stay tuned for accessing the web content.
Evaluation and Treatment of Iron Deficiency for the Practicing Oncologist | JCO Oncology Practice ascopubs.org/doi/10.1200/OP… @JCOOP_ASCO @ASCO @JCO_ASCO @OncoAlert
What’s up with Beta 2 microglobulin (B2M) and myeloma? Why is it the sole non-cytogenetic marker used in the new IMWG high risk definition? Why does it matter whether the creatinine is high or not? Thread 1/
1/ Excellent news for 🇺🇸 patients receiving CAR-T therapy! FDA has listened to data and relaxed CRS monitoring and driving restrictions for liso-cel for #lymsm / ide-cel for #MMsm. Huge step to lower time toxicity and disparities. Can this be fixed for all CAR-T products?
Beautiful paper by my good friend @pkarschnia, amazing to see all your academic progress in the last decade! Highly recommended reading out in @NatRevNeurol on all things CAR-T neurotoxicity - from ICANS to TIAN and MNTs👇
New online! Neurological complications of CAR T cell therapy for cancers bit.ly/4eqkbCe
#Myeloma Paper of the Day: Patients w/ >8.7 mos between last exposure to prior BCMA-directed therapy & teclistamab have significantly improved median PFS w/ tec (8.1 mos, 95% CI: 4.6-11.7) vs. pts with <8.7 mos (2.5 ms, 95% CI: 1.1-5.7), p=0.001: pubmed.ncbi.nlm.nih.gov/40562770/. #mmsm
Quality over quantity of life!! Out in @JCO_ASCO a prospective trial finding early palliative care during stem cell transplant isn’t just supportive... it’s transformative!! Better quality of life, less depression, mental health benefits lasting up to 6 months after treatment.…
Breaking: Big news for smoldering myeloma. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of a new indication for DARZALEX®(daratumumab) subcutaneous (SC) formulation as monotherapy for the treatment…
Proud to see our work finally out in #BloodICT @BloodPortfolio—thank you for the mentorship! It's been an incredible journey collaborating with the @MSKCancerCenter team these past years
Hot off press: Practical Use of Talquetamab in Relapsed/Refractory Multiple Myeloma: The MSKCC Experience in #BloodImmunologyAndCellTherapy sciencedirect.com/science/articl…
Just out: Guidelines for testing and reporting cytogenetic results in myeloma @BloodCancerJnl #OpenAccess Bookmark! Allows you to incorporate latest IMS/IMWG high risk criteria in practice. @lbaughn @RahulBanerjeeMD @Rfonsi1 nature.com/articles/s4140…
Nice summary of approved T-cell redirecting agents by Dr. Alvarez-Vallina #EHA2025 #mmsm #lymsm
Dr @AjaiChari shares the USCF guidelines for prevention and management of infections post BCMA BsAb and CAR T cells #mmsm #EHA2025 #EHA25